All In Biotech

Drug Trial Radar · NCT05358379

A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of THT140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

Apr 14, 2022

Primary completion

Nov 2028

Study completion May 2029

Sponsor

Lead sponsor
Tethra Biosciences Inc.Industry
Sponsor type
Industry
First posted
May 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.

Conditions

  • Solid Tumor, Adult Lymphoma

Interventions

  • THT140Drug

    THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated doseTime frame: 6 months
  2. Overall Response Rate (ORR)Time frame: 18 months

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center (MSKCC)

    New York, New York · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center/ University of Washington

    Seattle, Washington · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Not yet recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.